Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The spinal alpha-2 adrenergic receptor is a G protein-coupled receptor that mediates the effects of catecholamines, primarily norepinephrine and epinephrine, within the spinal cord. It plays a crucial role in modulating neurotransmitter release, neuronal excitability, and pain transmission. There are three main subtypes: α2A, α2B, and α2C, with α2A being the predominant subtype involved in analgesia. Activation of these receptors leads to inhibition of adenylyl cyclase, decreased cAMP production, and reduced neurotransmitter release, ultimately resulting in analgesia and other systemic effects like sedation and hypotension.
Gi protein activation, inhibition of adenylyl cyclase, decreased cAMP production, reduced PKA activity, hyperpolarization via increased potassium efflux, inhibition of voltage-gated calcium channels, reduced neurotransmitter release.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spinal Alpha-2 Adrenergic Receptor (α2-AR).